Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026

Same author

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

The American journal of gastroenterology·2026

Same author

Non-Invasive Testing in Metabolic Dysfunction Associated Fatty Liver Disease.

Archives of medical research·2025

Same author

A Rare, Atypical Presentation of Decompensated Cirrhosis: Isolated Transudative Hepatic Chylothorax Without Ascites.

Case reports in hepatology·2025

Same author

Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation.

Gastroenterology·2025

Same author

A red flag and a red herring-dual pathology of isolated polycystic liver disease with underlying epithelioid angiosarcoma resulting in recurrent hepatic cyst haemorrhage.

Journal of surgical case reports·2025

Same journal

Genetic and Genomic Insights Across the SLD Spectrum.

Clinical and molecular hepatology·2026

Same journal

Comparison of Clinical Practice Guidelines for Chronic Hepatitis B: Natural History Classification and Treatment Initiation.

Clinical and molecular hepatology·2026

Same journal

Clinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoring.

Clinical and molecular hepatology·2026

Same journal

Transitions from Combustible to Noncombustible Tobacco Use and Liver Outcomes in Steatotic Liver Disease.

Clinical and molecular hepatology·2026

Same journal

Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges.

Clinical and molecular hepatology·2026

Same journal

NAT10 deficiency in aging drives impaired liver regeneration by disrupting PARP10 in an ac4C-dependent manner.

Clinical and molecular hepatology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

MAFLD: How is it different from NAFLD?

Cameron Gofton^1,2,3,4, Yadhavan Upendran¹, Ming-Hua Zheng^5,6,7,8

¹Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia.

Clinical and Molecular Hepatology

|November 29, 2022

Summary

This summary is machine-generated.

Metabolic dysfunction-associated fatty liver disease (MAFLD) offers simpler diagnosis and better risk identification than nonalcoholic fatty liver disease (NAFLD). This updated terminology improves patient outcomes and research into liver conditions.

Keywords:

MAFLD MAFLD vs. NAFLD NAFLD

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Related Experiment Videos

Last Updated: Aug 19, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Area of Science:

Hepatology
Metabolic Disorders
Internal Medicine

Background:

Nonalcoholic fatty liver disease (NAFLD) is a prevalent condition linked to metabolic dysregulation.
The term NAFLD has limitations in diagnosis and patient stratification.
A shift towards a more precise terminology is needed.

Purpose of the Study:

To introduce and define Metabolic dysfunction-associated fatty liver disease (MAFLD) as a successor to NAFLD.
To highlight the diagnostic and clinical advantages of MAFLD over NAFLD.
To explore the impact of the MAFLD terminology on research and clinical practice.

Main Methods:

Review of diagnostic criteria for NAFLD and MAFLD.
Comparative analysis of clinical outcomes and risk stratification between NAFLD and MAFLD.
Discussion of adoption trends and research implications.

Main Results:

MAFLD criteria facilitate easier bedside diagnosis for primary care physicians.
MAFLD demonstrates superior risk prediction for liver and extrahepatic mortality compared to NAFLD.
MAFLD adoption by major societies is increasing due to its clarity and inclusivity.

Conclusions:

MAFLD represents a significant advancement over NAFLD terminology.
The MAFLD framework enhances identification of high-risk individuals and facilitates research.
MAFLD promotes a more accurate understanding and management of fatty liver disease related to metabolic dysfunction.